Data / Form D filings / EVIA Life Sciences Inc.
EVIA Life Sciences Inc.: Form D filing
EVIA Life Sciences Inc., a biotechnology company in Tokyo, Japan, filed a Form D with the SEC in 2026. The latest, on November 2, 2026, reports $700,002 sold of a $5.5 million offering to 1 investor.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- MIDTOWN TOWER 18F 9-7-1 AKASAKA, MINATO-KU, Tokyo, Japan, 107-6
- Phone
- 81 80 2105 3464
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2162667
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | New notice | $5,498,154 | $700,002 | $4,798,152 | 1 | Oct 23, 2026 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Kosuke Takishima | Executive Officer | |
| Joshua Raphael Schwab | Director | |
| Michael Kim | Director | |
| Takahiro Ochiya | Director |
Every Form D from the week of Nov 2, 2026 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what EVIA Life Sciences Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.